BioPharmSignal logoBioPharmSignal

Biotech News

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Terns Pharmaceuticals (TERN)Terns PharmaceuticalsCompany update

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March.

Open original release

Related news

ZNTLZentalis2026-05-13 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

NAMSNewAmsterdam Pharma2026-05-28 12:00 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

RLAYRelay Therapeutics2026-05-27 20:05 EST

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

VKTXViking Therapeutics2026-05-21 11:05 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

NAMSNewAmsterdam Pharma2026-05-11 12:41 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

ARGXArgenx2026-05-27 05:00 EST

argenx to Present at Upcoming Investor Conferences

ELVNEnliven Therapeutics2026-05-21 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-05-20 11:00 EST

Syndax Announces Participation in Upcoming Investor Conferences

EXELExelixis2026-05-07 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

View all latest news

Terns Pharmaceuticals

Terns Pharmaceuticals is a small-molecule biotech focused on oncology and metabolic disease opportunities. Its pipeline is built around targeted therapies with room for multiple shots on goal.

Recent company news

TERNTerns Pharmaceuticals2026-04-27 12:05 EST

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

TERNTerns Pharmaceuticals2026-04-02 20:05 EST

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

TERNTerns Pharmaceuticals2026-03-25 10:48 EST

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

TERNTerns Pharmaceuticals2026-02-25 21:05 EST

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

TERNTerns Pharmaceuticals2026-01-07 21:05 EST

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close
52.95 USD
Market cap
6.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States